Compare MNSB & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNSB | CRBP |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | 171 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.9M | 184.4M |
| IPO Year | N/A | 2014 |
| Metric | MNSB | CRBP |
|---|---|---|
| Price | $23.39 | $8.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 45.3K | ★ 447.6K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $3.77 | $116.00 |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $17.86 | $7.12 |
| 52 Week High | $25.29 | $20.56 |
| Indicator | MNSB | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 50.69 |
| Support Level | $22.00 | $7.86 |
| Resistance Level | $23.23 | $9.73 |
| Average True Range (ATR) | 0.62 | 0.45 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 1.88 | 35.51 |
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.